» Articles » PMID: 3543057

Insulinotropin: Glucagon-like Peptide I (7-37) Co-encoded in the Glucagon Gene is a Potent Stimulator of Insulin Release in the Perfused Rat Pancreas

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1987 Feb 1
PMID 3543057
Citations 224
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin secretion is controlled by a complex set of factors that include not only glucose but amino acids, catecholamines, and intestinal hormones. We report that a novel glucagon-like peptide, co-encoded with glucagon in the glucagon gene is a potent insulinotropic factor. The glucagon gene encodes a proglucagon that contains in its sequence glucagon and additional glucagon-like peptides (GLPs). These GLPs are liberated from proglucagon in both the pancreas and intestines. GLP-I exists in at least two forms: 37 amino acids GLP-I(1-37), and 31 amino acids, GLP-I(7-37). We studied the effects of synthetic GLP-Is on insulin secretion in the isolated perfused rat pancreas. In the presence of 6.6 mM glucose, GLP-I(7-37) is a potent stimulator of insulin secretion at concentrations as low as 5 X 10(-11) M (3- to 10-fold increases over basal). GLP-I(1-37) had no effect on insulin secretion even at concentrations as high as 5 X 10(-7) M. The earlier demonstration of specific liberation of GLP-I(7-37) in the intestine and pancreas, and the magnitude of the insulinotropic effect at such low concentrations, suggest that GLP-I(7-37) participates in the physiological regulation of insulin secretion.

Citing Articles

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.

He X, Zhao W, Li P, Zhang Y, Li G, Su H Front Pharmacol. 2025; 15:1483792.

PMID: 39902077 PMC: 11788294. DOI: 10.3389/fphar.2024.1483792.


A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.

Gul U, Aung T, Martin M, Farrukh D, Shah P, Lovely Z Cureus. 2025; 16(12):e76519.

PMID: 39872560 PMC: 11771532. DOI: 10.7759/cureus.76519.


The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.

Lu C, Xu C, Yang J Medicina (Kaunas). 2025; 61(1).

PMID: 39858999 PMC: 11767243. DOI: 10.3390/medicina61010017.


Design, Structure-Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists.

Sawyer J, Audie J, Swanson J, Diller D, Santiago S, Gribkoff V Molecules. 2025; 30(1.

PMID: 39795070 PMC: 11721672. DOI: 10.3390/molecules30010012.


Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes.

Holst J J Physiol. 2024; 602(24):6613-6629.

PMID: 39520693 PMC: 11649525. DOI: 10.1113/JP287461.


References
1.
Samols E, Marri G, Marks V . Interrelationship of glucagon, insulin and glucose. The insulinogenic effect of glucagon. Diabetes. 1966; 15(12):855-66. DOI: 10.2337/diab.15.12.855. View

2.
Orskov C, Holst J, Knuhtsen S, Baldissera F, Poulsen S, NIELSEN O . Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986; 119(4):1467-75. DOI: 10.1210/endo-119-4-1467. View

3.
PENHOS J, Wu C, Basabe J, Lopez N, WOLFF F . A rat pancreas-small gut preparation for the study of intestinal factor(s) and insulin release. Diabetes. 1969; 18(11):733-8. DOI: 10.2337/diab.18.11.733. View

4.
Albano J, Ekins R, Maritz G, Turner R . A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol (Copenh). 1972; 70(3):487-509. DOI: 10.1530/acta.0.0700487. View

5.
Dupre J, Ross S, WATSON D, Brown J . Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973; 37(5):826-8. DOI: 10.1210/jcem-37-5-826. View